1. Home
  2. BBY vs BIIB Comparison

BBY vs BIIB Comparison

Compare BBY & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Best Buy Co. Inc.

BBY

Best Buy Co. Inc.

HOLD

Current Price

$74.02

Market Cap

15.6B

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$181.61

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBY
BIIB
Founded
1966
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Video Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.6B
24.2B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
BBY
BIIB
Price
$74.02
$181.61
Analyst Decision
Buy
Buy
Analyst Count
19
23
Target Price
$84.24
$176.48
AVG Volume (30 Days)
4.1M
1.9M
Earning Date
11-25-2025
10-30-2025
Dividend Yield
5.12%
N/A
EPS Growth
N/A
N/A
EPS
3.02
10.97
Revenue
$41,825,000,000.00
$10,065,900,000.00
Revenue This Year
$1.77
$3.61
Revenue Next Year
$1.32
N/A
P/E Ratio
$24.54
$16.52
Revenue Growth
N/A
4.77
52 Week Low
$54.99
$110.04
52 Week High
$91.68
$185.17

Technical Indicators

Market Signals
Indicator
BBY
BIIB
Relative Strength Index (RSI) 40.86 72.92
Support Level $74.24 $174.53
Resistance Level $83.67 $182.94
Average True Range (ATR) 2.59 5.22
MACD -0.30 0.25
Stochastic Oscillator 11.07 83.54

Price Performance

Historical Comparison
BBY
BIIB

About BBY Best Buy Co. Inc.

With over $41 billion in consolidated 2024 sales, Best Buy is the largest pure-play consumer electronics retailer in the US, boasting roughly 8% share of the North American market and around 33% share of offline sales in the region, per our calculations, CTA, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the covid pandemic, have seen the US e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: